Navigation Links
Epilepsy Drug May Relieve Chronic Headaches

Researchers say the drug gabapentin (Neurontin) taken at 2,400 milligrams a day is an effective preventive measure // for people with chronic daily headaches.
Gabapentin is an approved anti-epileptic drug. Studies have also shown its success in treating other pain-related health issues like diabetic neuropathy, postherpetic neuralgia, and migraine headache. Since gabapentin often reduces migraines by more than 50 percent and chronic daily headaches often have migraine-like features, researchers in Australia conducted a double-blind, placebo-controlled study to determine the drug's specific effect on chronic daily headaches. This type of study is the gold standard of clinical research studies where neither the researchers nor the participants know who received the drug or an identical dummy substance, called a placebo.

For the study researchers recruited 133 patients who had headaches at least 15 days every month that lasted more than four hours at a time. The patients were randomly selected to receive gabapentin or a placebo for six weeks. After that period, none of the patients received either treatment for a week, and then each group switched to the opposite treatment for a second six weeks.

Results showed 36 percent of the patients taking 2,400 milligrams of gabapentin a day stopped having chronic daily headaches. Negative effects of the drug included vomiting, dizziness, dysarthria (problems speaking), sleepiness, and constipation.

Page: 1

Related medicine news :

1. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Epilepsy can be predicted
4. Epilepsy Drugs Can Enhance Risk of Birth Defects
5. Epilepsy Drug Helps Diabetic Nerve Damage
6. More Complications Seen In Women With Epilepsy
7. Epilepsy Drugs Found To Lead To Bone Loss
8. Another Use For Epilepsy Drugs
9. Epilepsy Patients Could Benefit From Pacemakers
10. Early Surgery For Treatment Of Epilepsy Questioned
11. Epilepsy Drug Valproate and Lamotrigine Linked To Malformed Fetus
Post Your Comments:

(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: